BAY 41-8543 (10-100 μg/kg; IV) produces small decreases in pulmonary arterial pressure, larger dose-dependent decreases in systemic arterial pressure, and increases in cardiac output[1].
BAY 41-8543 (0.003, 0.01, 0.03, 0.1, and 0.3mg/kg; iv) produces a dose-dependent and long-lasting decrease in blood pressure in anaesthetized rats. The blood pressure lowering effect of BAY 41-8543 lasts longer than the observation period of 30min. BAY 41-8543 (0.1, 0.3 and 1.0mgkg; oral) has maximal blood pressure lowering effects. The blood pressure lowering effects of the highest doses of BAY41-8543 lasts longer than the observation period of 120min[2].
BAY 41-8543 (3mg/kg; p.o.; twice daily; for 5 weeks) completely prevents the development of the increase in systolic blood pressure in 18-week-old renin transgenic rats (TGR(mRen2)27) on L-NAME treatment. BAY 41-8543 dramatically increases survival[2].
| Animal Model: | Adult male Sprague-Dawley rats weighing 325-450 g[1] |
| Dosage: | 10, 30, and 100 μg/kg |
| Administration: | IV |
| Result: | Produced small decreases in pulmonary arterial pressure, larger dose-dependent decreases in systemic arterial pressure, and increases in cardiac output.
|
